Paul K Stockman

Paul K Stockman

AstraZeneca, Sweden - Södertälje / Sweden
Medical and Health Sciences / Hematology
AD Scientific Index ID: 4400325
-
person_outline Paul K Stockman's MOST POPULAR ARTICLES
1-) Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trialNA Rizvi, BC Cho, N Reinmuth, KH Lee, A Luft, MJ Ahn, ...JAMA oncology 6 (5), 661-674, 20204142020
2-) Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled …M Maio, A Scherpereel, L Calabrò, J Aerts, SC Perez, A Bearz, ...The Lancet Oncology 18 (9), 1261-1273, 20174052017
3-) Vandetanib versus gefitinib in patients with advanced non–small-cell lung cancer: results from a two-part, double-blind, randomized phase II studyRB Natale, D Bodkin, R Govindan, BG Sleckman, NA Rizvi, A Capó, ...Journal of Clinical Oncology 27 (15), 2523-2529, 20092102009
4-) A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or …E Van Cutsem, YJ Bang, W Mansoor, RD Petty, Y Chao, D Cunningham, ...Annals of Oncology 28 (6), 1316-1324, 20171752017
5-) ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trialRB Natale, D Bodkin, R Govindan, B Sleckman, N Rizvi, A Capo, ...Journal of Clinical Oncology 24 (18_suppl), 7000-7000, 20061502006